In the context of precision medicine, assessment of minimal residual disease (MRD) has
been used in acute myeloid leukemia (AML) to direct individual treatment programs …

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia
cell population that gives rise to relapse of the disease. The detection of MRD is critical for …

Background CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of
initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) …

The differentiation of neural stem cells (NSCs) into neurons is proposed to be critical in
devising potential cell-based therapeutic strategies for central nervous system (CNS) …

Measurable residual disease (MRD) is highly prognostic for relapse and overall survival
(OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD …

Early response to induction chemotherapy is an important prognostic factor in B-
lymphoblastic leukemia (B-ALL). Here, we compare high-throughput sequencing (HTS) of …

Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other
biological vulnerabilities are transforming cancer treatment. As a result, many patients …

Nowadays, minimal residual disease (MRD) is accepted as the strongest independent
prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by molecular …

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved
in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL) …

This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab
ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with …